Clinical Trial Registration Number:NCT05315167 发布日期:2024.05 摘要号:2590 YF550-C1小分子抑制剂研究摘要海报细节展示如下: 题目: YF550-C1, an E3 ligase inhibitor of Cbl-b, to demonstrate T cell and NK cell ac-tivation and anti-tumor activities in syngeneic and PDX tumor model 网页链接: https...
,Nov. 12, 2021/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program...
BGB-15025, a potent, selective, small-molecule HPK1 inhibitor, showed preliminary antitumor effects in preclinical studies as monotherapy (mono tx) and enhanced antitumor effects in combination with TIS. We present dose-escalation results from an open-label, multicenter, phase 1 study (NCT04649385)...